Neurocrine Bio. (NBIX) Faces Headwind and Stops Offering Ingrezza Guidance - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Jeffrey Hung reiterated an Overweight rating and $120.00 price target on Neurocrine Bio. (NASDAQ: NBIX) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
